Two new drugs for renal cell carcinoma

Medical Letter on Drugs and Therapeutics

Volumn 49, Issue 1255, 2007, Pages 18-19

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HYPERICUM PERFORATUM EXTRACT; IMATINIB; IRINOTECAN; KETOCONAZOLE; RIFAMPICIN; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADRENAL DISEASE; ANOREXIA; BLEEDING; DIARRHEA; DRUG COST; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PANCREATITIS; RASH; SHORT SURVEY; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; STOMATITIS; VOMITING; ARTICLE; DRUG INTERACTION; KIDNEY TUMOR;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DRUG COSTS; DRUG INTERACTIONS; HUMANS; INDOLES; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES;

EID: 33847702094     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. HT Cohen and FJ McGovern. Renal-cell carcinoma. N Engl J Med 2005; 353:2477.
2. J Brugarolas. Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 2007; 356:185.
3. RJ Motzer et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516.
4. RJ Motzer et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16.
5. RJ Motzer et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115.
6. GD Demetri et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329.
7. Based on most recent data (January 2007) from retail pharmacies nationwide available from Wolters Kluwer Health.
8. MJ Ratain et al. Phase II placebo controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505.
9. B Escudier et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.
10. B Escudier et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24 suppl:217s, abstract 4501.